SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (2433)6/30/2005 3:36:40 AM
From: DewDiligence_on_SI  Read Replies (1) | Respond to of 3044
 
While Glivec, Femara, and Zometa are doing well, failure of the PTK and misconduct Vertex kinases deal + weak pipeline are not going in her favor.

1. PTK has not failed yet, although it did miss an interim endpoint in progression-free survival in one of two pivotal trials.

2. I would not characterize NVS’ oncology pipeline as weak.



To: Miljenko Zuanic who wrote (2433)6/30/2005 12:36:21 PM
From: tuck  Read Replies (1) | Respond to of 3044
 
Still, a record that only a very small number of oncology executives can surpass. Maybe someone at Genentech. Who else?

Cheers, Tuck


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News